Journal of Materials Science

, Volume 48, Issue 11, pp 3913–3925

Evaluation of biotinylated magnetic nanoparticles for tumour imaging

  • Ram Prakash Chauhan
  • Rashi Mathur
  • Gurjaspreet Singh
  • Narmada Bag
  • Sweta Singh
  • Krishna Chuttani
  • B. S. Hemanth Kumar
  • Satyam K. Agrawal
  • Anil K. Mishra
Article

Abstract

Target-specific nanoparticles with good stability, dispersibility and targeting properties are very desirable for in vivo applications like diagnosis and therapy. In this work, the potential of covalently biotinylated magnetic nanoparticles for targeting tumours has been analysed by various in vitro and in vivo studies. For quantitatively estimating the amount of biotin bound to the surface of magnetic nanoparticles, 4-Hydroxyazobenzene-2-carboxylic acid dye was used. Varying the pH conditions changes, the mean size and zeta potential and transverse relaxivity slightly, affects the contrast enhancing capability of the synthesized biotinylated magnetic nanoparticles minimally. Cytotoxicity of the synthesized nanoconjugate was analysed in two different cell lines HeLa and A549 by using sulpho-rhodamine B assay and tumour cell-targeting capability was analysed in HeLa cell lines by using confocal microscopy. The results of cytotoxicity analysis combined with intracellular uptake, biodistribution and gamma scintigraphy prove the tumour-targeting potential of the synthesized biocompatible biotinylated magnetic nanoparticle conjugate.

References

  1. 1.
    Corot C, Robert P, Idee JM, Port M (2006) Adv Drug Deliv Rev 58:1471CrossRefGoogle Scholar
  2. 2.
    Liong M, Lu J, Kovochich M, Xia T, Ruehm SG, Nel AE, Tamanoi F, Zink JI (2008) ACS Nano 2:889–896CrossRefGoogle Scholar
  3. 3.
    Lee HS, Kim EH, Shao H, Kwak BK (2005) J Magn Magn Mater 293:102–105CrossRefGoogle Scholar
  4. 4.
    Xu C, Sun S (2009) Dalton Trans 7:5583–5591CrossRefGoogle Scholar
  5. 5.
    Huber DL (2005) Small 1:482–501CrossRefGoogle Scholar
  6. 6.
    Mikhaylova M, Kim DK, Bobrysheva N, Osmolowsky M, Semenov V, Tsakalakos T, Muhammed M (2004) Langmuir 20:2472–2477CrossRefGoogle Scholar
  7. 7.
    Jain R (1996) Science 271:1079–1080CrossRefGoogle Scholar
  8. 8.
    Jain R (1987) Cancer Metastasis Rev 6:559–593CrossRefGoogle Scholar
  9. 9.
    Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, Jain RK (1998) Proc Natl Acad Sci 95:4607–4612CrossRefGoogle Scholar
  10. 10.
    Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WCW (2009) Nano Lett 9:1909–1915CrossRefGoogle Scholar
  11. 11.
    Maeda H (2001) Adv Enzyme Regul 41:189–207CrossRefGoogle Scholar
  12. 12.
    Maeda H, Wu J, Sawa T, Matsumura Y, Hori K (2000) J Control Release 65:271–284CrossRefGoogle Scholar
  13. 13.
    Wunderbaldinger P, Josephson L, Weissleder R (2002) Bioconjug Chem 13:264–268CrossRefGoogle Scholar
  14. 14.
    Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W (1998) Magn Reson Med 40:236–242CrossRefGoogle Scholar
  15. 15.
    Weissleder R, Kelly K, Sun EY, Shtatland T, Josephson L (2005) Nat Biotechnol 23:1418–1423CrossRefGoogle Scholar
  16. 16.
    Bonnemain B (1998) J Drug Target 6:167–174CrossRefGoogle Scholar
  17. 17.
    Wang YX, Hussain SM, Krestin GP (2001) Eur Radiol 11:2319–2331CrossRefGoogle Scholar
  18. 18.
    Chauhan RP, Singh G, Singh S, Bag N, Patra M, Vadera SR, Mishra AK, Mathur R (2011) Cancer Nano 2:111–120CrossRefGoogle Scholar
  19. 19.
    Tannous BA, Grimm J, Perry KF, Chen JW, Weissleder R, Breakefield XO (2006) Nat Methods 3:391–396CrossRefGoogle Scholar
  20. 20.
    Sakahara H, Saga T (1999) Adv Drug Deliv Rev 37:89–101CrossRefGoogle Scholar
  21. 21.
    Paganelli G et al (1992) Eur J Nucl Med 19:322–329CrossRefGoogle Scholar
  22. 22.
    Kobayashi H, Kawamoto S, Star RA, Waldmann TA, Brechbiel MW, Choyke PL (2003) Bioconjug Chem 14:1044–1047CrossRefGoogle Scholar
  23. 23.
    Tilborg GFV et al (2008) Magn Reson Med 60:1444–1456CrossRefGoogle Scholar
  24. 24.
    Ashwell G, Harford J (1982) Ann Rev Biochem 51:531–554CrossRefGoogle Scholar
  25. 25.
    Townsend R, Stahl P (1981) Biochem J 194:209–214Google Scholar
  26. 26.
    Toth CA, Thomas P (1992) Hepatology 16:255–266CrossRefGoogle Scholar
  27. 27.
    Schechter B, Silberman R, Arnon R, Wilchek M (1990) Eur J Biochem 189:327–331CrossRefGoogle Scholar
  28. 28.
    Artemov D, Mori N, Ravi R, Bhujwalla ZM (2003) Cancer Res 63:2723–2727Google Scholar
  29. 29.
    Kobayashi H, Sakahara H, Endo K, Hosono M, Yao ZS, Toyama S, Konishi J (1995) Jpn J Cancer Res 86:310–314CrossRefGoogle Scholar
  30. 30.
    Yao Z, Zhang M, Sakahara H, Saga T, Arano Y, Konishi J (1998) J Natl Cancer Inst 90:25–29CrossRefGoogle Scholar
  31. 31.
    Yao Z, Zhang M, Sakahara H, Saga T, Nakamoto Y, Sato N, Zhao S, Arano Y, Konishi J (1998) Ann Nucl Med 12:115–118CrossRefGoogle Scholar
  32. 32.
    Gabius HJ, Engelhardt R, Cramer F (1986) Anticancer Res 6:573–578Google Scholar
  33. 33.
    Lotan R, Raz A (1988) Ann N Y Acad Sci 551:385–388CrossRefGoogle Scholar
  34. 34.
    Jeong JM, Kinuya S, Paik CH, Saga T, Sood VK, Carrasquillo JA, Neumann RD, Reynolds JC (1994) Nucl Med Biol 21:935–940CrossRefGoogle Scholar
  35. 35.
    Kobayashi H, Sakahara H, Hosono M, Yao ZS, Toyama S, Endo K, Konishi J (1994) J Nucl Med 35:1677–1684Google Scholar
  36. 36.
    Hama Y, Urano Y, Koyama Y, Kamiya M, Bernardo M, Paik RS, Krishna MC, Choyke PL, Kobayashi H (2006) Neoplasia 8:607–612CrossRefGoogle Scholar
  37. 37.
    Lee SJ, Jeong JR, Shin SC, Kim JC, Kim JD (2004) J Magn Magn Mater 282:147–150CrossRefGoogle Scholar
  38. 38.
    Bautista MC, Miguel OB, Morales MP, Serna CJ, Verdaguer SV (2005) J Magn Magn Mater 293:20–27CrossRefGoogle Scholar
  39. 39.
    Xu Z, Liu Q, Finch JA (1997) Appl Surf Sci 120:269–278CrossRefGoogle Scholar
  40. 40.
    Ma M, Zhang Y, Yu W, Shen H, Zhang H, Gu N (2003) Coll Surf A Physicochem Eng Asp 212:219–226CrossRefGoogle Scholar
  41. 41.
    Yamaura M, Camilo RL, Sampaio LC, Macedo MA, Nakamura M, Toma HE (2004) J Magn Magn Mater 279:210–217CrossRefGoogle Scholar
  42. 42.
    Hofstetter H, Morpurgo M, Hofstetter O, Bayer EA, Wilchek M (2000) Anal Biochem 284:354–366CrossRefGoogle Scholar
  43. 43.
    Keepers YP, Pizao PE, Peters GJ, Otte JA, Winograd B, Pinedo HM (1991) Eur J Cancer 27:897–900CrossRefGoogle Scholar
  44. 44.
    Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) J Natl Cancer Inst 82:1107–1112CrossRefGoogle Scholar
  45. 45.
    Sonvico F, Mornet S, Vasseur S, Dubernet C, Jaillard D, Degrouard J, Hoebeke J, Duguet E, Colombo P, Couvreur P (2005) Bioconjug Chem 16:1181–1188CrossRefGoogle Scholar
  46. 46.
    Weissleder R, Bogdanov A, Neuwelt EA, Papisov M (1995) Adv Drug Deliv Rev 16:321–334CrossRefGoogle Scholar
  47. 47.
    Sun C, Lee JSH, Zhang M (2008) Adv Drug Deliv Rev 60:1252–1265CrossRefGoogle Scholar
  48. 48.
    Rosebrough SF (1993) Nucl Med Biol 20:663–668CrossRefGoogle Scholar
  49. 49.
    Salem AK, Rose F, Oreffo R, Yang X, Davies MC, Mitchell JR, Roberts CJ, Trenkic SS, Tendler S, Williams PM, Shakesheff KM (2003) Adv Mater 15:210–213CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ram Prakash Chauhan
    • 1
    • 2
    • 4
  • Rashi Mathur
    • 1
  • Gurjaspreet Singh
    • 2
  • Narmada Bag
    • 1
  • Sweta Singh
    • 1
  • Krishna Chuttani
    • 1
  • B. S. Hemanth Kumar
    • 3
  • Satyam K. Agrawal
    • 5
  • Anil K. Mishra
    • 1
  1. 1.Division of Cyclotron and Radiopharmaceutical SciencesInstitute of Nuclear Medicine and Allied Sciences, Defence Research and Development OrganizationDelhiIndia
  2. 2.Department of ChemistryPanjab UniversityChandigarhIndia
  3. 3.Division of NMRInstitute of Nuclear Medicine and Allied Sciences, Defence Research and Development OrganizationDelhiIndia
  4. 4.Department of ChemistryS.V.G.C. GhumarwinBilaspurIndia
  5. 5.Department of PharmaceuticalsNational Institute of Pharmaceutical Education & ResearchMohaliIndia

Personalised recommendations